CHESHIRE, Conn.--(BUSINESS WIRE)--Independent investigators reported today that patients with paroxysmal nocturnal hemoglobinuria (PNH) who were treated long-term with Soliris® (eculizumab) achieved survival comparable to that of an age- and gender-matched normal population. (1) Findings from this investigator-led analysis were reported in an oral presentation today at the 52nd American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando. Soliris is a first-in-class terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN).
